<DOC>
	<DOCNO>NCT00091637</DOCNO>
	<brief_summary>In set reperfusion therapy acute myocardial infarction use primary percutaneous intervention ( PCI ) , body 's inflammatory system involve complement cascade may harmful . This study test safety efficacy novel complement inhibitor , pexelizumab reduce mortality 30 day .</brief_summary>
	<brief_title>Pexelizumab Conjunction With Angioplasty Acute Myocardial Infarction ( APEX-AMI )</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Cardiac symptom least 20 minute within past 6 hour ; Will undergo primary PCI ; Has ECG evidence acute high risk ST elevation myocardial infarction ; Willing able follow least 12 month . Isolated low risk inferior wall myocardial infarction ; Received fibrinolytic therapy ; History complement deficiency ; Suspected neisserial infection ; Participating investigational study ; Pregnancy ; Previous enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>